Merck KGaA 2015 AR2
The report highlights the company's strategic transformation into a global science and technology company, marked by the landmark acquisition of Sigma-Aldrich for US$ 17 billion and a major corporate brand relaunch. Financially, net sales rose by 13% to €12.8 billion, and EBITDA pre exceptionals grew by 7.1% to €3.6 billion. In research and development, the company advanced its immuno-oncology alliance with Pfizer, initiating six pivotal trials for avelumab. Additionally, the company expanded its OLED business and inaugurated a modular Innovation Center in Darmstadt.
Company: Merck KGaA
Sector: Manufacturing
Country: Germany
Year: 2015
Type: AR2
Pages: 266
Back to company
Merck KGaA
Annual Report
The report highlights the company's strategic transformation into a global science and technology company, marked by the landmark acquisition of Sigma-Aldrich for US$ 17 billion and a major corporate brand relaunch. Financially, net sales rose by 13% to €12.8 billion, and EBITDA pre exceptionals grew by 7.1% to €3.6 billion. In research and development, the company advanced its immuno-oncology alliance with Pfizer, initiating six pivotal trials for avelumab. Additionally, the company expanded its OLED business and inaugurated a modular Innovation Center in Darmstadt.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2015
Reporting Period
Jan 1, 2015 - Dec 31, 2015
Fiscal Year
2015
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Women on Board
Women in Management
Workplace Fatalities
Employees